Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Study
100%
Paclitaxel
100%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
100%
Previously Untreated
100%
Topotecan
100%
Febrile Neutropenia
50%
Group Performance
25%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
Neutropenia
25%
Survival Rate
25%
Anemia
25%
High Incidence
25%
Chemotherapy
25%
Median Survival
25%
Performance Status
25%
Oncology
25%
Overall Response Rate
25%
Partial Response
25%
Thrombocytopenia
25%
Esophagitis
25%
Hypotension
25%
Myelosuppression
25%
4-cycle
25%
Initial Treatment
25%
3-year Survival
25%
Response Evaluation
25%
Stomatitis
25%
2-year Survival
25%
Medicine and Dentistry
Paclitaxel
100%
Small Cell Lung Cancer
100%
Topotecan
100%
Febrile Neutropenia
40%
Anemia
20%
Survival Rate
20%
Esophagitis
20%
Neutropenia
20%
Oncology
20%
Hypotension
20%
Thrombocytopenia
20%
Stomatitis
20%
Bone Marrow Suppression
20%
Granulocyte Colony Stimulating Factor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Small Cell Lung Cancer
100%
Febrile Neutropenia
40%
Survival Rate
20%
Chemotherapy
20%
Neutropenia
20%
Thrombocytopenia
20%
Esophagitis
20%
Granulocyte Colony Stimulating Factor
20%
Anemia
20%
Bone Marrow Suppression
20%
Hypotension
20%
Stomatitis
20%